CompletedEUCTR 2005-003180-23
An 8-week, double blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy and safety of 2 fixed doses of SR58611A (175 mg q12 and 350 m...
This historical record does not confirm current site availability.
Historical research recordCzechiaAnxiety
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Czechia
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 480
- Sponsor
- sanofi-aventis recherche & développement
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Czechia
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2005-003180-23
- Official title
Show the full official title
An 8-week, double blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy and safety of 2 fixed doses of SR58611A (175 mg q12 and 350 m...
Get this study by email
Recruitment & locations
CompletedCzechia
Registry details
Historical country statuses
- Czechia — Completed
Questions about this study
Who is behind this study?
The study sponsor is sanofi-aventis recherche & développement.
